Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease DOI Creative Commons
Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex metabolic disorder characterized by hepatic lipid accumulation and subsequent inflammation. This condition closely linked to syndrome obesity, with its prevalence rising due sedentary lifestyles high-calorie diets. The pathogenesis of MAFLD involves multiple factors, including insulin resistance, lipotoxicity, oxidative stress, inflammatory responses. gut microbiota plays crucial role in development, dysbiosis contributing inflammation through various mechanisms, such as enhanced intestinal permeability the translocation bacterial products like lipopolysaccharide (LPS). Microbial metabolites, short-chain acids (SCFAs) bile acids, influence function immune responses, potential implications for progression. Specific microbiome signatures have been identified patients, offering diagnostic therapeutic targets. Moreover, gut-derived toxins, endotoxins, lipopolysaccharides, trimethylamine-N-oxide significantly damage inflammation, highlighting interplay between health. review comprehensively examines MAFLD, focusing on underlying pathogenic biomarkers, emerging microbiome-targeted strategies management.

Language: Английский

Metformin as a disease-modifying therapy in osteoarthritis: bridging metabolism and joint health DOI Creative Commons
Iryna Halabitska, Pavlo Petakh, Oleksandr Kamyshnyi

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 19, 2025

Background Osteoarthritis (OA) and impaired glucose tolerance (IGT) frequently coexist, leading to compounded clinical metabolic challenges. This study investigates the effects of metformin in improving both outcomes (pain, stiffness, physical function) parameters (inflammatory markers, lipid profile, BMI) patients with knee OA IGT. Methods The included 60 diagnosed Participants were divided into two groups: 26 received standard treatment without (Without Metf), while 34 (500 mg twice daily) for 3 months, addition (With Metf). Clinical assessments (WOMAC, Lequesne Algofunctional Index, KOOS, VAS) markers (CRP, NLR, SOD, measured before treatment, after 1 month, months. Results With Metf group showed significantly greater improvements pain, function, quality life compared Without group. Metformin also led significant reductions inflammatory profiles health indicators. demonstrated enhanced BMI, waist-to-hip ratio, waist-to-height ratio. Furthermore, need increased NSAID doses was predicted by factors such as pain severity markers. Conclusion effectively alleviates osteoarthritis symptoms improves Further research is needed explore its long-term on joint health, potential role management

Language: Английский

Citations

0
Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease DOI Creative Commons
Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex metabolic disorder characterized by hepatic lipid accumulation and subsequent inflammation. This condition closely linked to syndrome obesity, with its prevalence rising due sedentary lifestyles high-calorie diets. The pathogenesis of MAFLD involves multiple factors, including insulin resistance, lipotoxicity, oxidative stress, inflammatory responses. gut microbiota plays crucial role in development, dysbiosis contributing inflammation through various mechanisms, such as enhanced intestinal permeability the translocation bacterial products like lipopolysaccharide (LPS). Microbial metabolites, short-chain acids (SCFAs) bile acids, influence function immune responses, potential implications for progression. Specific microbiome signatures have been identified patients, offering diagnostic therapeutic targets. Moreover, gut-derived toxins, endotoxins, lipopolysaccharides, trimethylamine-N-oxide significantly damage inflammation, highlighting interplay between health. review comprehensively examines MAFLD, focusing on underlying pathogenic biomarkers, emerging microbiome-targeted strategies management.

Language: Английский

Citations

0